Cellmat Therapeutics Decides to Acquire 2 Million Shares of Etrial Stock
Cellmat Therapeutics announced on the 10th that it has decided to acquire 2 million shares of Etrial, a cosmetics wholesale and retail company. The acquisition amount is 1 billion KRW, and the shareholding ratio after acquisition will be 50.48%.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
